|Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients|
|Lin, MaoFang1; Hou, Jian2; Chen, WenMing3; Huang, XiaoJun4; Liu, ZhuoGang5; Zhou, YuHong6; Li, Yan7; Zhao, Taiyun8; Wang, LinNa8; Wu, Kwang-Wei8; Shen, ZhiXiang9|
|关键词||Bortezomib Chinese Multiple Myeloma Observational Study Refractory Relapsed Response|
|刊名||ADVANCES IN THERAPY|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, Research & Experimental ; Pharmacology & Pharmacy|
|研究领域[WOS]||Research & Experimental Medicine ; Pharmacology & Pharmacy|
|关键词[WOS]||DEXAMETHASONE ; EPIDEMIOLOGY ; STRATEGIES ; PARADIGMS ; RISK|
Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic backgrounds. The efficacy and safety of bortezomib was assessed in patients from China with relapsed/refractory MM in a real-world scenario.
This prospective, non-interventional, observational study enrolled both male and female Chinese patients, aged a parts per thousand yen18 years and diagnosed with relapsed or refractory MM. Administration of intravenous bortezomib at 1.3 mg/m(2) was recommended twice a week for 2 weeks (days 1, 4, 8 and 11), followed by a 10-day rest period (maximum of 8 cycles) and a follow-up every 12 weeks for 3 years. Efficacy assessments included best response, objective response rate (ORR), time to response, duration of response, and overall survival. Safety was also assessed.
A total of 517 patients were enrolled with a median age of 58.7 years. Patients predominantly had immunoglobulin G type (46.2%) and stage III (47.8%) myeloma. Overall, 202 (42.3%) patients had partial response as best response, ORR was 88.9% and the proportion of patients exhibiting complete response was 24.7%. The median time to response observed was 27 (21-40) days. Median time to progression was 415 days and median overall survival was 475 days. Thrombocytopenia (14.4%) was the most common adverse event.
Bortezomib demonstrated clinical response in majority of patients and was well tolerated in this observational study in Chinese patients with relapsed/refractory MM.
|作者单位||1.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China|
2.Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China
3.Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
5.China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China
6.Zhejiang Prov Tradit Chinese Med Hosp, Dept Hematol, Shenyang, Liaoning, Peoples R China
7.China Med Univ, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China
8.Xian Janssen Pharmaceut Co, Beijing, Peoples R China
9.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
|Lin, MaoFang,Hou, Jian,Chen, WenMing,et al. Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients[J]. ADVANCES IN THERAPY,2014,31(10):1082-1094.|
|APA||Lin, MaoFang.,Hou, Jian.,Chen, WenMing.,Huang, XiaoJun.,Liu, ZhuoGang.,...&Shen, ZhiXiang.(2014).Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients.ADVANCES IN THERAPY,31(10),1082-1094.|
|MLA||Lin, MaoFang,et al."Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients".ADVANCES IN THERAPY 31.10(2014):1082-1094.|